Joke Bilcke
Overview
Explore the profile of Joke Bilcke including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
52
Citations
937
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Li X, Bilcke J, Asare E, Wenger C, Kwon J, Bont L, et al.
medRxiv
. 2024 Jul;
PMID: 39072019
Objective: Non-disease-specific WHO-CHOICE unit costs are often used in cost and cost-effectiveness studies in the absence of country-specific data. This study aims to compare reported country-specific disease costs and the...
2.
Li X, Bilcke J, Beutels P
Lancet Reg Health Am
. 2024 Jan;
29:100657.
PMID: 38205370
No abstract available.
3.
Antillon M, Li X, Willem L, Bilcke J, Jit M, Beutels P
PLoS Med
. 2023 Jul;
20(7):e1004250.
PMID: 37459352
Background: Respiratory syncytial virus (RSV) infections are among the primary causes of death for children under 5 years of age worldwide. A notable challenge with many of the upcoming prophylactic...
4.
Koltai M, Moyes J, Nyawanda B, Nyiro J, Munywoki P, Tempia S, et al.
BMC Med
. 2023 Apr;
21(1):120.
PMID: 37004062
Background: Respiratory syncytial virus (RSV) causes a substantial burden of acute lower respiratory infection in children under 5 years, particularly in low- and middle-income countries (LMICs). Maternal vaccine (MV) and...
5.
Mao Z, Li X, Dacosta-Urbieta A, Billard M, Wildenbeest J, Korsten K, et al.
Vaccine
. 2023 Mar;
41(16):2707-2715.
PMID: 36941154
Background: Respiratory syncytial virus (RSV) causes a considerable disease burden in young children globally, but reliable estimates of RSV-related costs and health-related quality-of-life (HRQoL) are scarce. This study aimed to...
6.
Phillips M, Antillon M, Bilcke J, Bar-Zeev N, Limani F, Debellut F, et al.
BMC Infect Dis
. 2023 Mar;
23(1):143.
PMID: 36890448
Background: Several prolonged typhoid fever epidemics have been reported since 2010 throughout eastern and southern Africa, including Malawi, caused by multidrug-resistant Salmonella Typhi. The World Health Organization recommends the use...
7.
Getaneh A, Li X, Mao Z, Johannesen C, Barbieri E, van Summeren J, et al.
Vaccine
. 2023 Feb;
41(9):1623-1631.
PMID: 36737318
Background: Respiratory syncytial virus (RSV) imposes a substantial burden on pediatric hospital capacity in Europe. Promising prophylactic interventions against RSV including monoclonal antibodies (mAb) and maternal immunizations (MI) are close...
8.
Li X, Hodgson D, Flaig J, Kieffer A, Herring W, Beyhaghi H, et al.
Value Health
. 2022 Nov;
26(4):508-518.
PMID: 36442831
Objectives: Model-based cost-effectiveness analyses on maternal vaccine (MV) and monoclonal antibody (mAb) interventions against respiratory syncytial virus (RSV) use context-specific data and produce varied results. Through model comparison, we aim...
9.
Bilcke J, Beutels P
Pharmacoeconomics
. 2022 Sep;
40(10):1013-1014.
PMID: 36163539
No abstract available.
10.
Li X, Bilcke J, van der Velden A, Bruyndonckx R, Coenen S, Bongard E, et al.
Eur J Health Econ
. 2022 Sep;
24(6):909-922.
PMID: 36131214
Background: Oseltamivir is usually not often prescribed (or reimbursed) for non-high-risk patients consulting for influenza-like-illness (ILI) in primary care in Europe. We aimed to evaluate the cost-effectiveness of adding oseltamivir...